Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein

Anti-Cancer Drugs

Volumn 10, Issue 8, 1999, Pages 719-728

  Sparreboom, Alex ^a   Planting, André S T ^a   Jewell, Roxanne C ^b   Van Der Burg, Maria E L ^a   Van Der Gaast, Ate ^a   De Bruijn, Peter ^a   Loos, Walter J ^a   Nooter, Kees ^a   Chandler, LuWanda H ^b   Paul, Elaine M ^b   Wissel, Paul S ^b   Verweij, Jaap ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Doxorubicin; Drug resistance; GF120918; P glycoprotein; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; ELACRIDAR; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TOXICITY; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG URINE LEVEL; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; NEUTROPHIL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE COUNT;

EID: 0033390989     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199909000-00005     Document Type: Article

References (35)

1. 1. Gros P, Neriah YB, Croop JM, Housman DE. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986; 323: 728-31.
2. 2. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cells. Science 1983; 221: 1285-8.
3. 3. Raderer M, Scheithauer W. Clinical trials of agents that reverse multidrug resistance: a literature review. Cancer 1393; 72: 3553-63.
4. 4. Ozols RF, Cunnion RE, Klecker RW, et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987; 5: 641-547.
5. 5. Erlichman C, Moore M, Thiessen JJ, et al. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res 1993; 53: 4837-42.
6. 6. List AF, Spier C, Greer J, et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993; 11: 1652-60.
7. 7. Bartlett NL, Lum BL, Fisher GA, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1994; 12: 835-42.
8. 8. Rushing DA, Raber SR, Rodvold KA, Piscitelli SC, Plank GS, Tewksbury DA. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer 1994; 74: 834-41.
9. 9. Wilson WH, Jamis-Dow C, Bryant G, et al. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J Clin Oncol 1995; 13: 1985-94.
10. 10. Berg SL, Tolcher A, O'Shaughnessy JA, et al. Effect of r-verapamil of the pharmacokinetics of paclitaxel in women with breast cancer. J Clin Oncol 1995; 13: 2039-42.
11. 11. Boote DJ, Dennis IF, Twentyman PR, et al. Phase I study of etoposide with PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 1996; 14: 610-8.
12. 12. Giaccone G, Linn SC, Welink L, et al. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 1997; 3: 2005-15.
13. 13. Relling MV. Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Ther Drug Monit 1996; 18: 350-6.
14. 14. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, and acridinecarboxamide derivative. Cancer Res 1993; 53: 4595-602.
15. 15. Brouwer KR, Mellon-Kusibab K. Effect of GF120918 (GW918), a potent multidrug resistance (MDR) modulator, on the pharmacokinetics (PK) and pharmacodynamics (PD) of doxorubicin (DOX) in the dog. Pharm Res 1996; 13: S455 (abstr).
16. 16. Planting A, Van der Gaast A, Sparreboom A, et al. Phase I and pharmacokinetic (PK) study targeting a 100 ng/ml plasma concentration of the potent multidrug resistance (MDR) modulator GF120918 (GF) with doxorubicin (dox) in patients with advanced solid tumors. Proc Am Soc Clin Oncol 1998; 17: 199a (abstr).
17. 17. De Bruijn P, Verweij J, Loos WJ, et al. Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography. Anal Biochem 1999; 266: 216-21.
18. 18. Witherspoon SM, Emerson DL, Kerr BM, Lloyd TL, Dalton WS, Wissel PS. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin Cancer Res 1996; 2: 7-12.
19. 19. Powell MD. Methods for finding the minimum of a function of several variables without calculating derivatives. Comput J 1964; 7: 155-62.
20. 20. Akaike H. An information criterion (AIC). Math Sci 1976; 14: 5-11.
21. 21. Schwarz G. Estimating the dimension of a model. Ann Stat 1978; 5: 461-5.
22. 22. Rowland M, Tozer, TN. Clinical pharmacokinetics: concepts and applications, 3rd edn. Baltimore, MD: Williams & Wilkins 1995.
23. 23. Piscitelli SC, Rodvold KA, Rushing DA, Tewksbury DA. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther 1993; 53: 555-61.
24. 24. Robert J, Illiadis A, Hoemi B, Cano JP, Durand M, Lagarde C. Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. Eur J Cancer 1982; 18: 739-45.
25. 25. Mross K, Mayer U, Hamm K, Burk K, Hossfeld D. Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans. Eur J Clin Pharmacol 1990; 39: 507-13.
26. 26. Twelves CJ, Dobbs NA, Aldhous M, Harper PG, Rubens RD, Richards MA. Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer. Cancer Chemother Pharmacol 1991; 28: 302-7.
27. 27. Ferry D, Moore M, Bartlett NL, et al. Phase I and pharmacokinetic (PK) study targeting a 500 ng/ml plasma concentration of the potent multidrug resistance (MDR) modulator GF120918 (GF) with doxorubicin (dox) in patients with advanced solid tumors. Proc Am Soc Clin Oncol 1998; 17: 240a (abstr).
28. 28. Ratain MJ, Schilsky RL, Conley BA, Egorin MJ. Pharmacodynamics in cancer chemotherapy. J Clin Oncol 1990; 8: 1739-53.
29. 29. Böhme M, Büchler M, Müller M, Keppler, D. Differential inhibition by cyclosporins of the primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett 1993; 333: 193-6.
30. 30. Büchler M, Böhme M, Ortlepp H, Keppler D. Functional reconstitution of ATP-dependent transports from the solubilized hepatocyte canalicular membrane. Eur J Biochem 1994; 224: 345-52.
31. 31. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 1997; 100: 2430-6.
32. 32. Sparreboom A, Van Tellingen O, Nooijen WJ, Beijnen JH. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 1996; 56: 2112-5.
33. 33. Webster LK, Cosson EJ, Stokes KH, Millward MJ. Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br J Cancer 1996; 73: 522-4.
34. 34. Ellis AG, Crinis NA, Webster LK. Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. Cancer Chemother Pharmacol 1995; 38: 81-7.
35. 35. Van Asperen J, Van Tellingen O, Tijssen F, Schinkel AH, Beijnen JH. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br J Cancer 1999; 79: 108-13.